Share chart Adaptimmune Therapeutics plc
Extended chart
Simple chart
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, биофармацевтическая компания, работающая на клинической стадии, специализируется на предоставлении новых клеточных методов лечения, в первую очередь, пациентам с солидными опухолями в Соединенных Штатах. Платформа Т-клеток специфического пептидного рецептора повышенной аффинности (SPEAR) позволяет идентифицировать цели рака. more detailsMain settings
IPO date
2015-05-06
ISIN
US00653A1079
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0.7851 | 9 |
| P/BV | 11.8 | 1 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -26.79 | 0 |
| ROE | -275.74 | 0 |
| ROIC | -65.72 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -1.41 | 10 |
| Debt/Ratio | 0.3017 | 10 |
| Debt/Equity | 19.76 | 0 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 4350.8 | 10 |
| Yield Ebitda, % | -56.11 | 0 |
| Yield EPS, % | -68.81 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 0.2459 $ | 0 $ | 0 $ | -2.16 % | 0 % | 0 % |
| Week | 0.283 $ | 0 $ | 0 $ | -14.98 % | 0 % | 0 % |
| Month | 0.2744 $ | 0.2406 $ | 0.2925 $ | -12.32 % | 0 % | 0 % |
| Three month | 0.2333 $ | 0.197 $ | 0.3239 $ | 3.13 % | 0 % | 0 % |
| Half a year | 0.572 $ | 0.197 $ | 0.6543 $ | -57.94 % | 0 % | 0 % |
| Year | 1.24 $ | 0.197 $ | 1.39 $ | -80.6 % | 0 % | 0 % |
| 3 years | 2.02 $ | 0.197 $ | 2.53 $ | -88.09 % | 0 % | 0 % |
| 5 years | 8.99 $ | 0.197 $ | 10.78 $ | -97.32 % | 0 % | 0 % |
| 10 years | 0.197 $ | 0.197 $ | 20.24 $ | 122.13 % | 0 % | 0 % |
| Year to date | 0.62 $ | 0.197 $ | 0.6543 $ | -61.19 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Matrix Capital Management | 38 974 185 | 25.2 |
| NEA Management Company, LLC | 17 079 778 | 11.04 |
| Baillie Gifford and Company | 15 912 140 | 10.29 |
| Long Focus Capital Management, LLC | 12 086 915 | 7.82 |
| Baker Brothers Advisors, LLC | 10 969 282 | 7.09 |
| PFM Health Sciences, LP | 10 423 135 | 6.74 |
| Mpm Asset Management, LLC | 5 555 461 | 3.59 |
| MPM BioImpact Capital LLC | 5 095 912 | 3.29 |
| Bank of America Corporation | 4 697 954 | 3.04 |
| Tang Capital Management, LLC | 4 387 238 | 2.84 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. | Co-Founder & Chief Business & Strategy Officer | 709.84k | 1967 (58 years) |
| Dr. Juli P. Miller Ph.D. | VP of Corporate Affairs & Investor Relations | N/A | |
| Ms. Joanna Brewer Ph.D. | Chief Scientific Officer | N/A | 1976 (49 years) |
| Mr. Adrian G. Rawcliffe | CEO, Principal Accounting Officer & Director | 693.64k | 1972 (53 years) |
| Ms. Kerry Sharp | Senior VP & General Council | N/A | |
| Dr. Elliot Norry B.A., M.D. | Chief Medical Officer | 549.05k | 1964 (61 year) |
| Mr. Gavin Hilary James Wood ACA, BA (Hons) | Chief Financial Officer | 508.22k | 1970 (55 years) |
| Dana Lynch | Senior Director of Corporate Communications | N/A | |
| Mr. William C. A. Bertrand Jr., Esq., J.D. | Chief Operating Officer | 1965 (60 years) | |
| Mr. John Lunger | Chief Patient Supply Officer | 1970 (55 years) |
About company
Address: United Kingdom, Abingdon OX RX, 60 Jubilee Avenue - Open in google maps, Open in yandex maps
Website: https://www.adaptimmune.com
Website: https://www.adaptimmune.com
